Non-invasive Imaging With [18F]VM4-037 — [18F]VM4-037

Stage 4 Cancer Clinical Trial

Official title:
Non Invasive Imaging of [18F]VM4-037 With Positron-Emission-Tomography (PET): A Phase I Trial

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to determine the toxicity of the hypoxia PET-tracer [18F]-VM4-037 in cancer patients in two dose-steps:

- Step 1 (3-6 patients): a single dose of maximum 8 mCi (296 MBq) dose of [18F]VM4-037 via a bolus IV injection.

- Step 2 (3-6 patients): a single dose of maximum 12 mCi (444 MBq) dose of [18F]VM4-037 via a bolus IV injection

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Stage 4 Cancer

Clinical Trial Details

NCT number	NCT00935142
Study type	Interventional
Source	Maastricht Radiation Oncology
Contact
Status	Withdrawn
Phase	Phase 1
Start date	January 2012
Completion date	November 2012

View Details

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT00408070` - Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Phase 2